SCHEDULE 13G/A: Farallon Capital Discloses 3.4% Stake in Forte Biosciences, Inc.
Beneficial Ownership Report
Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.4% in Forte Biosciences, Inc. as of December 31, 2024.
Summary
- Farallon Capital and its various affiliated funds and managing members collectively beneficially own 221,027 shares of Forte Biosciences, Inc. Common Stock.
- This aggregate ownership represents 3.4% of Forte Biosciences, Inc.'s outstanding common stock.
- The total beneficial ownership comprises 35,000 existing shares and 186,027 Class A Common Stock Purchase Warrants, each exercisable for one share.
- The filing was made by multiple Farallon entities, including Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Offshore Investors II, L.P., and their general partners and managing members.
- The event triggering this filing occurred on December 31, 2024.
Sentiment
Score: 6
Explanation: The document is a standard beneficial ownership disclosure. The presence of a significant institutional investor like Farallon Capital can be seen as a moderately positive signal, indicating a degree of confidence in the company, although the filing itself is neutral in tone.
Positives
- The disclosure of a significant stake by an institutional investor like Farallon Capital can be viewed positively, indicating confidence in Forte Biosciences, Inc.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Forte Biosciences, Inc.'s future performance or strategic direction.
Industry Context
Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock but do not intend to influence or change control of the issuer. This filing indicates Farallon Capital's passive investment position in Forte Biosciences, Inc., a common practice among large investment firms managing diversified portfolios.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member of Farallon General Partner and Manager of FCIP V General Partner and F5MI General Partner | NA | Patrick (Cheng) Luo | 01/01/2025 | Became a managing member/manager, leading to deemed beneficial ownership of the Farallon Funds' holdings. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which required the filing of this statement, indicating the beneficial ownership position as of this date. |
| 01/01/2025 | Effective date when Patrick (Cheng) Luo became a managing member of Farallon General Partner and a manager of FCIP V General Partner and F5MI General Partner, becoming a deemed beneficial owner. |
| 02/10/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Forte Biosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.